NasdaqGS - Nasdaq Real Time Price USD
BridgeBio Pharma, Inc. (BBIO)
68.63 -0.29 (-0.42%)
At close: June 23 at 4:00:00 PM EDT
69.95 +1.32 (+1.92%)
After hours: June 23 at 6:56:38 PM EDT
Trade BBIO on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for BBIO
Chart does not reflect overnight price.
- Previous Close
68.92 - Open
68.57 - Bid 50.15 x 100
- Ask 88.16 x 100
- Day's Range
68.03 - 69.90 - 52 Week Range
41.80 - 84.94 - Volume
2,398,956 - Avg. Volume
2,589,131 - Market Cap (intraday)
13.442B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-3.74 - Earnings Date (est.) Aug 4, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
102.28
Recent News
View More
Performance Overview
Trailing total returns as of 6/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
BBIO
10.28%
S&P 500 (^GSPC)
7.60%
1-Year Return
BBIO
62.73%
S&P 500 (^GSPC)
22.24%
3-Year Return
BBIO
338.25%
S&P 500 (^GSPC)
69.39%
5-Year Return
BBIO
15.64%
S&P 500 (^GSPC)
73.64%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/22/2026
Market Cap
13.49B
Enterprise Value
15.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.89
Price/Book (mrq)
--
Enterprise Value/Revenue
25.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-124.42%
Return on Assets (ttm)
-27.98%
Return on Equity (ttm)
--
Revenue (ttm)
579.96M
Net Income Avi to Common (ttm)
-721.55M
Diluted EPS (ttm)
-3.74
Balance Sheet and Cash Flow
Total Cash (mrq)
940.19M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-317.91M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreBridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice TargetBridgeBio Earnings: Three Phase 3 Trial Successes Reinforce Growth Trajectory
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target